| scholarly article | Q13442814 |
| P50 | author | Karina Salvatierra | Q61013710 |
| Juan Ángel Patiño-Galindo | Q61130863 | ||
| F X López-Labrador | Q71257032 | ||
| Fernando González-Candelas | Q28322701 | ||
| P2093 | author name string | Fernando González-Candelas | |
| Juan Ángel Patiño-Galindo | |||
| Karina Salvatierra | |||
| P2860 | cites work | Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. | Q42993387 |
| Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development | Q45364246 | ||
| The Calculated Genetic Barrier for Antiretroviral Drug Resistance Substitutions Is Largely Similar for Different HIV-1 Subtypes | Q56778335 | ||
| EASL Recommendations on Treatment of Hepatitis C 2015 | Q58324800 | ||
| MUSCLE: a multiple sequence alignment method with reduced time and space complexity | Q21284290 | ||
| Clinical significance of hepatitis C virus genotypes | Q24514512 | ||
| MUSCLE: multiple sequence alignment with high accuracy and high throughput | Q24613456 | ||
| euHCVdb: the European hepatitis C virus database | Q27477695 | ||
| The Evolution of the Major Hepatitis C Genotypes Correlates with Clinical Response to Interferon Therapy | Q27489040 | ||
| New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0 | Q27860476 | ||
| MEGA5: Molecular Evolutionary Genetics Analysis Using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Methods | Q27860929 | ||
| HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors | Q28481038 | ||
| Similar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep pyrosequencing | Q28542443 | ||
| Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and Windows | Q29547183 | ||
| Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence | Q29616009 | ||
| Genetic Heterogeneity of Hepatitis C Virus: Quasispecies and Genotypes | Q29619748 | ||
| CD-HIT Suite: a web server for clustering and comparing biological sequences | Q33686347 | ||
| Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource | Q33777199 | ||
| Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus | Q34044333 | ||
| Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives | Q34045760 | ||
| Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients | Q36384127 | ||
| Virus pathogen database and analysis resource (ViPR): a comprehensive bioinformatics database and analysis resource for the coronavirus research community | Q36432773 | ||
| Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients | Q37426527 | ||
| Resistance to direct antiviral agents in patients with hepatitis C virus infection | Q37652739 | ||
| The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection | Q38113079 | ||
| Epidemiology and natural history of HCV infection. | Q38118578 | ||
| Importance of HCV genotype 1 subtypes for drug resistance and response to therapy | Q38193551 | ||
| Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors | Q38849307 | ||
| Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α. | Q39626790 | ||
| Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061. | Q40967696 | ||
| Identification of the NS5B S282T resistant variant and two novel amino acid substitutions that affect replication capacity in hepatitis C virus-infected patients treated with mericitabine and danoprevir | Q41076434 | ||
| Global origin and transmission of hepatitis C virus nonstructural protein 3 Q80K polymorphism | Q41666553 | ||
| Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: novel insights about targeted genotyping approaches | Q42205040 | ||
| Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability | Q42599975 | ||
| Signature pattern analysis: a method for assessing viral sequence relatedness | Q42605822 | ||
| Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects | Q42980129 | ||
| Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates | Q42980467 | ||
| The Los Alamos hepatitis C sequence database | Q42987686 | ||
| Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir | Q42990234 | ||
| Naturally occurring substitutions conferring resistance to hepatitis C virus polymerase inhibitors in treatment-naive patients infected with genotypes 1-5. | Q42990352 | ||
| The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank | Q42991856 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| Hepatitis C virus | Q708693 | ||
| P304 | page(s) | 2402-2416 | |
| P577 | publication date | 2016-02-08 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Comprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwide Isolates of Viral Genotypes 1 to 6 | |
| P478 | volume | 60 |
| Q41921724 | Baseline NS5A Resistance Associated Substitutions May Impair DAA Response in Real-World Hepatitis C Patients. |
| Q57482963 | Baseline dasabuvir resistance in Hepatitis C virus from the genotypes 1, 2 and 3 and modeling of the NS5B-dasabuvir complex by the approach |
| Q37174078 | Biomedical Mutation Analysis (BMA): A software tool for analyzing mutations associated with antiviral resistance |
| Q39182744 | Characterization of clinical predictors of naturally occurring NS3/NS4A protease polymorphism in genotype 1 hepatitis C virus mono and HIV co-infected patients |
| Q40677674 | Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein |
| Q90398259 | Computational analysis of naturally occurring resistance-associated substitutions in genes NS3, NS5A, and NS5B among 86 subtypes of hepatitis C virus worldwide |
| Q55078028 | Evolutionary Analysis Provides Insight Into the Origin and Adaptation of HCV. |
| Q59358332 | GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo |
| Q47596851 | Genotype and genetic variation of HCV infections with low-risk factors in Putian coastal regions, China |
| Q64252207 | Geographic Distribution of HCV-GT3 Subtypes and Naturally Occurring Resistance Associated Substitutions |
| Q97885926 | HCV Replicon Systems: Workhorses of Drug Discovery and Resistance |
| Q47564117 | Hepatitis C virus deep sequencing for sub-genotype identification in mixed infections: A real-life experience |
| Q38887954 | Hepatitis C virus resistance to the new direct-acting antivirals |
| Q39307349 | Natural occurrence of NS5B inhibitor resistance-associated variants in Brazilian patients infected with HCV or HCV and HIV. |
| Q58725182 | Natural polymorphisms in the resistance associated sites of HCV-G1 NS5B domain and correlation with geographic origin of HCV isolates |
| Q44104489 | Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients. |
| Q49911983 | Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection. |
| Q47397635 | Prevalence of NS5B resistance-associated variants in treatment-naïve Asian patients with chronic hepatitis C. |
| Q55379857 | Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. |
| Q45324124 | Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China. |
| Q59126211 | Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus |
| Q50098527 | Resistance analysis of genotype 3 HCV indicates subtypes inherently resistant to NS5A inhibitors. |
| Q38757351 | The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation. |
| Q92876947 | The Investigation of Drug Resistance Substitutions in NS3 Protease Sequence of Hepatitis C Virus from Non-Responder Patients |
Search more.